0001209191-18-015887.txt : 20180302
0001209191-18-015887.hdr.sgml : 20180302
20180302173628
ACCESSION NUMBER: 0001209191-18-015887
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180228
FILED AS OF DATE: 20180302
DATE AS OF CHANGE: 20180302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Polymeropoulos Mihael Hristos
CENTRAL INDEX KEY: 0001355537
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34186
FILM NUMBER: 18663556
MAIL ADDRESS:
STREET 1: 9605 MEDICAL CENTER DRIVE SUITE 300
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001347178
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030491827
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
BUSINESS PHONE: 202-734-3400
MAIL ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-28
0
0001347178
Vanda Pharmaceuticals Inc.
VNDA
0001355537
Polymeropoulos Mihael Hristos
2200 PENNSYLVANIA AVENUE
SUITE 300E
WASHINGTON
DC
20037
1
1
0
0
President and CEO
Common Stock
2018-02-28
4
A
0
60000
A
1243838
D
Common Stock
2018-03-01
4
S
0
60966
18.7154
D
1182872
D
Employee Stock Option (Right to Buy)
18.85
2018-02-28
4
A
0
140000
0.00
A
2028-02-27
Common Stock
140000
140000
D
Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning February 28, 2019, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
The price reported in Column 4 is a weighted average price. The Reporting The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.30 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The option vests in forty-eight (48) equal monthly installments beginning on February 28, 2018, provided the Reporting Person remains continuously employed by the Issuer through each vesting date.
/s/ Mihael Polymeropoulos
2018-03-02